Xconomy | Seattle - Business + Technology in the Exponential Economy

AVI Nails Down $30M

AVI Biopharma, the Bothell, WA-based developer of RNA therapies, said today it has raised another $30 million through a stock offering. The company (NASDAQ: AVII) said it sold 21 million new shares of common stock, in addition to 8.5 million warrants to buy shares, in an offering underwritten by Jefferies & Company. AVI, which recently moved its headquarters from Portland, OR to Bothell, has raised money from a variety of foundations, and government agencies to support its experimental treatments for Duchenne Muscular Dystrophy, and Ebola virus.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: